Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated April 2026
| Key Takeaways - On April 23, 2026, the DOJ moved FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III under federal law. - This is one of the most significant federal drug policy shifts in 50+ years - testosterone is also a Schedule III substance. - THC may suppress LH and impact Leydig cell testosterone production, but men already on TRT are in a fundamentally different position. - A major 2025 study linked cannabis abuse/dependence with a nearly 4-fold higher short-term risk of erectile dysfunction. - Rescheduling will finally unlock rigorous federal research on cannabis and male hormonal health - answers are coming. - Moderate use, especially XXX-dominant or low-THC formulations, appears less concerning than heavy THC dependence for men on TRT. |
If you follow men's health news, you probably saw the headlines on April 23, 2026: the U.S. Department of Justice announced it was immediately moving medical marijuana out of Schedule I and into Schedule III of the Controlled Substances Act. For those of us in the testosterone and hormone optimization community, this is worth understanding - both for what it means right now and for what it may unlock in future research.
For decades, marijuana sat in the same federal category as heroin - a drug supposedly with 'no accepted medical use and high abuse potential.' Meanwhile, testosterone, which many of us depend on for quality of life, is already a Schedule III substance. That inconsistency was glaring, and now a piece of it has been corrected.
Here is what changed, what the existing evidence says about cannabis and male hormonal health, and what all of this means if you are currently on TRT.
What you will learn in this article:
• Exactly what the April 2026 rescheduling order does and does not do
• How THC and XXX interact with the hormonal axis - the HPG connection
• What the latest large-scale studies say about cannabis, testosterone, and ED
• Whether men on TRT need to worry about cannabis use
• What rescheduling means for research into cannabis and men's health
What Changed on April 23, 2026?
Acting Attorney General Todd Blanche signed an order immediately placing two categories of cannabis products into Schedule III: (1) FDA-approved drug products containing marijuana, and (2) marijuana products regulated under a qualifying state medical marijuana license. The action flows directly from a December 18, 2025, Executive Order signed by President XXXXX directing agencies to expand medical marijuana and cannabidiol research.The DOJ simultaneously announced a new expedited DEA administrative hearing beginning June 29, 2026, to consider broader rescheduling of marijuana - meaning recreational cannabis sold through adult-use dispensaries could follow later. That broader rescheduling question remains open, and legal challenges from anti-cannabis advocacy groups are expected.
| Category | Old Schedule | New Schedule (as of 4/23/2026) | Practical Effect |
| FDA-approved cannabis products (e.g., Epidiolex, Marinol) | Schedule I | Schedule III | Immediate - full federal research access |
| State-licensed medical marijuana | Schedule I | Schedule III | Immediate - reduced regulatory burden for researchers |
| Recreational / adult-use cannabis | Schedule I | Schedule I (unchanged for now) | No change yet - pending June 29 hearing |
| Testosterone (for context) | N/A | Schedule III | Already here - same category as medical cannabis now |
To put this in plain terms: medical marijuana now sits in the same federal scheduling tier as testosterone, ketamine, and Tylenol with codeine. That is a meaningful symbolic and practical shift, even if it does not mean cannabis is suddenly available everywhere without restriction.
The biggest near-term benefit is for researchers. Under Schedule I, scientists faced strict approval processes, limited supply access, and heavy compliance requirements when studying cannabis therapeutics - including any potential effects on hormones, pain, sleep, and sexual function. Those barriers are now substantially lower for medical cannabis research.
How Does Cannabis Actually Affect Testosterone and Male Hormones?
This is where the science gets genuinely interesting - and genuinely complicated. The research on cannabis and male testosterone is not settled, and that is exactly why rescheduling matters so much for our community.The HPG Axis Connection - Why THC Has Hormonal Effects
The endocannabinoid system (ECS) is not separate from your hormonal system - it is intertwined with it. Cannabinoid receptors, specifically CB1 and CB2, are present in male reproductive organs including the Leydig cells of the testes. Leydig cells are where most of your natural testosterone production happens.THC, the psychoactive compound in cannabis, binds to CB1 receptors and has been shown to have a regulatory effect on the hypothalamic-pituitary-gonadal (HPG) axis - the same hormonal cascade that governs testosterone production. This means THC can, in theory, signal the brain to reduce LH secretion, which in turn reduces the testes' testosterone output. For men on TRT, this mechanism matters less directly - you are not relying on your own LH signal - but it still has implications for overall hormonal milieu and Leydig cell health.
What the Research Shows - A Mixed but Clarifying Picture
Here is the honest summary of where the evidence stands:• Earlier smaller studies were split: some found cannabis users had slightly elevated testosterone (possibly due to the cortisol-blunting effects of THC or simple demographics - cannabis users tend to be younger), while others found mild suppression with heavy use.
• A 2017 NHANES-based study of 3,027 U.S. men found modestly higher testosterone in cannabis users compared to non-users. A Danish study of 1,215 men similarly found testosterone about 7% higher in self-reported marijuana smokers - though cigarette smokers also had elevated testosterone, complicating the interpretation.
• The most important recent data comes from a 2025 TriNetX database analysis of over 1.5 million U.S. men - far larger than any prior study. This is the research our community needs to take seriously.
| Outcome | Risk in Cannabis Abuse/Dependence Group | Timeframe |
| Erectile dysfunction | ~4x higher risk | 3 months - 1 year |
| Testosterone deficiency (<300 ng/dL) | ~2.2x higher risk | 3 months - 1 year |
| PDE5 inhibitor (e.g., Viagra) prescription | ~4x higher risk | 3 months - 1 year |
| Erectile dysfunction (longer-term) | ~1.2x higher risk | 3 - 5 years |
| Testosterone deficiency (longer-term) | No significant association | 3 - 5 years |
The critical word in that table is abuse/dependence. This study looked at men with a formal cannabis abuse or dependence diagnosis - heavy, problematic users - not occasional users. The short-term risk elevations are striking, but they likely reflect a dose and frequency relationship that does not apply to someone using a cannabis edible twice a week for sleep.
What About DHT? What the ExcelMale Community Has Noticed
Our forum has a thread specifically examining cannabis and DHT (dihydrotestosterone) - the potent androgen that drives libido and certain physical characteristics. Early lab research from the 1970s found that THC, CBN, and smoked cannabis condensate could inhibit DHT binding to the androgen receptor in rat prostate tissue. More recently, ExcelMale members who've tracked bloodwork during cannabis use report generally stable DHT levels, particularly with XXX-dominant or low-THC products. However, individuals differ, and frequent high-THC use may have different effects than occasional low-dose use.Cannabis also appears to lower estradiol and increase prolactin in some research contexts. Lower estradiol could theoretically reduce libido and erectile function in some men (particularly those who are already low). Elevated prolactin can suppress testosterone production and libido. Again, these findings are from specific usage patterns and individual physiology varies widely.
Should Men on TRT Be Concerned About Cannabis Use?
Here is the practical takeaway for our community: men on TRT are in a meaningfully different position than men with natural testosterone production.When you are on exogenous testosterone, your hypothalamic-pituitary axis is largely suppressed anyway - your testosterone level is determined by what you inject or apply, not by LH signaling to your Leydig cells. So the mechanism by which THC might suppress natural testosterone production is largely bypassed. You are not going to crash your T levels from cannabis use if you are on a well-managed TRT protocol.
That said, cannabis use is not without relevant considerations for men on TRT:
• Erectile function: The ED risk association in heavy users is real and the mechanisms are not fully understood. Vascular effects, neural effects, and lifestyle factors may all play a role. If you are already managing ED on TRT, adding significant cannabis use is not without risk.
• Sleep quality: Many ExcelMale members report using low-dose cannabis (especially 1:1 XXX:THC formulations) specifically for sleep. The evidence here is mixed - cannabis may help with sleep onset but can reduce REM sleep with chronic use, and dependence concerns exist with long-term nightly use. Use strategically, not habitually.
• Sperm and fertility: If you are trying to preserve fertility or using hCG to maintain testicular function, cannabis is worth more caution. THC appears to affect sperm motility, morphology, and count in some studies. This matters if fertility is a priority.
• Drug interactions: Cannabis is metabolized through the CYP450 system. If you take other medications - particularly those with narrow therapeutic windows - discuss cannabis use with your prescriber.
• Cardiovascular considerations: Cannabis use, particularly smoked forms, has been associated with cardiovascular effects including transient blood pressure changes. Men on TRT who already manage hematocrit and cardiovascular risk should be mindful of delivery method.
| Bottom Line for Men on TRT - Moderate, occasional use - especially XXX-dominant or low-THC products - appears to carry far less hormonal risk than the alarming early data might suggest. - Heavy, dependent use is a different matter: the 2025 TriNetX study showing 4x elevated ED risk and 2x elevated testosterone deficiency risk was specific to abuse/dependence-level use. - You are not relying on your HPG axis if you are on TRT, which blunts the main testosterone-suppression mechanism. - Get bloodwork. If you are a regular cannabis user and your TRT protocol seems harder to dial in, or your libido and erectile function have declined, add this variable to your investigation. - Talk to your TRT provider about your cannabis use - this will become more relevant as research expands. |
What Does Rescheduling Mean for Research Into Cannabis and Men's Health?
This is arguably the most important long-term implication of the April 2026 action. The research gaps in this field have been enormous and frustrating precisely because Schedule I status imposed severe restrictions on who could study cannabis, under what conditions, and with what supply.With state-licensed medical cannabis now in Schedule III, researchers can:
• Obtain cannabis for clinical trials with far less regulatory friction
• Conduct dose-response studies separating THC, XXX, and other cannabinoids
• Run prospective studies on men with hypogonadism who use medical cannabis
• Study TRT users specifically - a population that has been virtually absent from the existing literature
• Investigate cannabis as a potential adjunct for chronic pain, sleep, and PTSD in men managing hormone health
The 2025 TriNetX study is the best large-scale data we have right now, and it was necessarily retrospective and observational. We need prospective, controlled studies that can actually establish causation, dose-response relationships, and which specific cannabinoid ratios carry the most risk or benefit for men's hormonal health. Schedule III makes those studies viable in a way they were not before.
For our community, this could also mean better answers on questions we have been debating in forum threads for years: Does XXX affect SHBG? Does occasional THC use affect estradiol in men on TRT? Can specific cannabinoid formulations improve sleep quality without compromising hormonal optimization? We may finally get rigorous answers.
Frequently Asked Questions
Does using cannabis while on TRT lower my testosterone levels?
Not directly - not in the same way it might for a man with natural testosterone production. On TRT, your testosterone level is set primarily by your exogenous dose, not by LH signaling. The mechanism through which THC suppresses natural testosterone (via the HPG axis) is largely bypassed when you are on exogenous T. That said, very heavy cannabis use is associated with erectile dysfunction and other hormonal disruptions that can affect your overall TRT experience.Is XXX safer than THC for men on TRT?
Current evidence suggests XXX has fewer direct hormonal effects than THC. XXX does not bind to CB1 receptors the same way THC does. Many men in our community use XXX for sleep, pain management, and anxiety with minimal apparent impact on their TRT outcomes. However, the research base for XXX specifically in men on TRT is still thin, and high-dose XXX may have its own metabolic and drug interaction considerations.Will I face legal problems using medical cannabis while on TRT?
This depends entirely on your state and how your medical marijuana is obtained. The April 2026 rescheduling specifically covers FDA-approved cannabis products and state-licensed medical marijuana. If you hold a valid state medical marijuana card and obtain cannabis through a licensed dispensary, your use is covered under the new Schedule III designation. Recreational cannabis in adult-use states remains Schedule I federally until the June 29 hearing process concludes.Can cannabis affect my hematocrit while on TRT?
There is no strong direct evidence that cannabis significantly affects hematocrit. However, smoked cannabis affects lung function and respiratory health, which can indirectly impact oxygen-carrying capacity and cardiovascular markers. For men already managing elevated hematocrit on TRT, the cardiovascular considerations of regular cannabis use - particularly smoked forms - are worth discussing with your provider.What should I tell my TRT doctor about cannabis use?
Be honest. More providers are now in states where medical or recreational cannabis is legal, and the conversation is less fraught than it once was. Let your doctor know the frequency, amount, and form (smoked, edibles, tinctures) of your use. Rescheduling will only accelerate the normalization of this conversation in clinical settings.Related ExcelMale Forum Discussions
1. Cannabis and DHT - What Members Have Found in Their Bloodwork - Members share personal bloodwork data from concurrent cannabis and TRT use, with specific focus on DHT levels and androgen receptor binding.2. Success with 1:1 Ratio of XXX:THC for Sleep Problems - A physician-moderated thread discussing the practical use of balanced XXX:THC formulations for sleep improvement, including long-term considerations and dependence risks.
3. Are Cannabis and Cannabinoids Safe? Community Discussion - A comprehensive community debate covering safety data, contraindications, cardiovascular considerations, and real-world usage experiences from ExcelMale members.
4. THC - Indica for Sleep? Current Member Experiences - Members currently discussing indica strains for sleep management alongside TRT protocols.
5. US Federal and State Regulations on Testosterone and HCG - Background on how testosterone and HCG are currently scheduled, providing important context for understanding where cannabis now sits in the same scheduling framework.
Key References
1. U.S. Department of Justice. (2026, April 23). Justice Department Places FDA-Approved Marijuana Products in Schedule III. Office of Public Affairs.2. Asanad K, et al. (2025). Association of cannabis abuse/dependence on risks of erectile dysfunction and testosterone deficiency using a large claims database analysis. The Journal of Sexual Medicine, 22(5), 711.
3. Thistle JE, et al. (2017). Marijuana use and serum testosterone concentrations among U.S. males. Andrology, 5(4), 732-738.
4. Lim J, Squire E, Jung KM. (2023). Phytocannabinoids, the Endocannabinoid System and Male Reproduction. Frontiers in Endocrinology.
5. Hedges JC, et al. (2022). Chronic exposure to delta-9-tetrahydrocannabinol impacts testicular volume and male reproductive health in rhesus macaques. Fertility & Sterility.
6. Rossato M, Pagano C, Vettor R. (2008). The cannabinoid system and male reproductive functions. Journal of Neuroendocrinology, 20(Suppl 1), 90-93.
7. Du Plessis SS, et al. (2015). The effects of cannabis on male reproductive functions: a systematic review. Current Urology Reports, 16(6), 42.
8. Belladelli F, et al. (2022). Effects of recreational cannabis on testicular function in primary infertile men. Fertility & Sterility.
9. Block RI, et al. (1991). Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug and Alcohol Dependence, 28(2), 121-128.
10. CNN Politics. (2026, April 23). Justice Department reclassifies state-licensed medical marijuana as a less dangerous drug.
Conclusion
The DOJ's April 23, 2026, order rescheduling medical marijuana to Schedule III is a watershed moment in U.S. drug policy. For men in the TRT and hormone optimization community, it carries two distinct layers of meaning.In the near term, the most important thing to understand is this: if you are managing your testosterone and occasionally using cannabis for sleep, pain, or recovery, the existing evidence does not suggest you are in dangerous territory - especially if you are using XXX-dominant or low-THC products in moderation. The alarm bells in the research attach to heavy, dependent use, not occasional therapeutic use.
In the longer term, this rescheduling will unlock the research our community has been waiting for. Questions about cannabis, testosterone, estradiol, DHT, erectile function, and sleep that we have been debating in forum threads for years will now be answerable through properly designed clinical trials. The data is coming - and that is genuinely good news.
As always, get your blood work done, stay informed, and have an open conversation with your TRT provider about all the factors in your protocol - including cannabis use. The landscape is changing fast.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy or medical treatment. The legal status of cannabis varies by state and continues to evolve - verify current laws in your jurisdiction.
About ExcelMale
ExcelMale.com is one of the world's leading men's health forums, with over 24,000 members and a 20+ year archive of peer discussions on testosterone replacement therapy, hormone optimization, peptides, sexual health, and preventive medicine. The community is founded and moderated by Nelson Vergel, a chemical engineer, 30+ year TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. ExcelMale bridges peer-reviewed clinical research with the lived experience of thousands of men navigating hormone health.
